Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Suspended 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Thrombocythemia, Essential 1Primary Myelofibrosis 1Polycythemia Vera 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Lung Neoplasms 1Leukemia, Myeloid, Acute 1

Interventions

Specimen Handling 6Cytarabine 6fludarabine 5Biopsy 5fludarabine phosphate 4Whole-Body Irradiation 4Tacrolimus 4Granulocyte Colony-Stimulating Factor 4Cyclophosphamide 4venetoclax 3decitabine and cedazuridine drug combination 3Mycophenolic Acid 3Melphalan 3Injections 3Idarubicin 3CPX-351 3Busulfan 3Blood Specimen Collection 3ruxolitinib 2nilotinib 2luspatercept 2ivosidenib 2asciminib 2Thiotepa 2Sirolimus 2Peripheral Blood Stem Cell Transplantation 2Methotrexate 2Liposomes 2Gemtuzumab 2Filgrastim 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Myeloproliferative Disorders × iadademstat × 30 days × Clear all
NCT06661915 2026-05-29

A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)

National Cancer Institute (NCI)

Phase 2 Suspended
62 enrolled
Myeloid

Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Myelodysplastic-Myeloproliferative Diseases, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡